Autonomix Medical (AMIX) said Monday three patients responded to radio frequency pain management with femoral access in an ongoing clinical trial evaluating its potential to manage pain in pancreatic cancer patients without the use of opioids.
Two patients in the same group, but treated with brachial access, didn't show improvement in their pain scores, or worsened, the company said, but all paitents treated with the technology were able to eliminate their opioid use at four to six weeks post-procedure.
The company said the preliminary results came from the first five "lead-in" patients in its ongoing proof-of-concept human trial assessing the delivery of transvascular energy to ablate problematic nerves and mitigate pain in pancreatic cancer pain patients.
The trial is expected to finish enrolment by yearend, the company said.
The company's technology platform uses a catheter-based microchip sensing array antenae that can detect neural signals. Once target nerves are identified, the treatment uses radio frequency ablation technology to kill targeted nerves, the company said.
Autonomix shares soared more than 150% in recent Monday premarket activity.
Price: 19.59, Change: +11.88, Percent Change: +154.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.